Inotrope versus Placebo Therapy in Cardiogenic Shock: Rationale and Study Design of the CAPITAL DOREMI2 Trial.

[1]  D. Brodie,et al.  Inotropes, vasopressors, and mechanical circulatory support for treatment of cardiogenic shock complicating myocardial infarction: a systematic review and network meta-analysis , 2022, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.

[2]  Arthur S Slutsky,et al.  Mechanical circulatory support in the treatment of cardiogenic shock , 2022, Current opinion in critical care.

[3]  Rebecca Mathew,et al.  Inotrope and vasopressor use in cardiogenic shock: what, when and why? , 2022, Current opinion in critical care.

[4]  D. Brodie,et al.  Optimal Perfusion Targets in Cardiogenic Shock , 2022, JACC. Advances.

[5]  S. Fernando,et al.  Lactate Clearance as a Surrogate for Mortality in Cardiogenic Shock: Insights From the DOREMI Trial , 2022, Journal of the American Heart Association.

[6]  S. Fernando,et al.  Inotropes for cardiogenic shock - Six of one, half a dozen of the other. , 2021, Anaesthesia Critical Care & Pain Medicine.

[7]  J. Russo,et al.  Implications of Myocardial Infarction on Management and Outcome in Cardiogenic Shock , 2021, Journal of the American Heart Association.

[8]  S. Fernando,et al.  Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock. , 2021, The New England journal of medicine.

[9]  H. Thiele,et al.  Arterial Lactate in Cardiogenic Shock: Prognostic Value of Clearance Versus Single Values. , 2020, JACC. Cardiovascular interventions.

[10]  L. Otterspoor,et al.  Vasopressors and Inotropes in Acute Myocardial Infarction Related Cardiogenic Shock: A Systematic Review and Meta-Analysis , 2020, Journal of clinical medicine.

[11]  C. Granger,et al.  Acute Cardiovascular Care Association position statement for the diagnosis and treatment of patients with acute myocardial infarction complicated by cardiogenic shock: A document of the Acute Cardiovascular Care Association of the European Society of Cardiology , 2020, European heart journal. Acute cardiovascular care.

[12]  H. Thiele,et al.  PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock , 2017, The New England journal of medicine.

[13]  E. Ohman,et al.  Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association , 2017, Circulation.

[14]  G. Schuler,et al.  Intraaortic balloon support for myocardial infarction with cardiogenic shock. , 2012, The New England journal of medicine.

[15]  R. Strasser,et al.  Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction* , 2008, Critical care medicine.

[16]  A. Cohen-Solal,et al.  Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. , 2007, JAMA.

[17]  F. Van de Werf,et al.  Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. , 2007, JAMA.

[18]  K. Adams,et al.  In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, Journal of the American College of Cardiology.

[19]  Christopher M O'Connor,et al.  Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. , 2003, Journal of the American College of Cardiology.

[20]  T. LeJemtel,et al.  Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. , 2002, American heart journal.

[21]  J. Cleland,et al.  Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial , 2002, The Lancet.

[22]  R. Califf,et al.  Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. , 2002, JAMA.

[23]  H. White,et al.  Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. , 1999, The New England journal of medicine.

[24]  Joo Myung Lee,et al.  La escala de vasoactivos inotrópicos como predictora de mortalidad de adultos con shock cardiogénico tratados con y sin ECMO , 2019, Revista Española de Cardiología.

[25]  D. Baim,et al.  Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. , 1986, Circulation.